ADMA Q1 revenue up 40% to $114.8M; raises FY2025/2026 guidance; authorizes $500M buyback

ADMA BIOLOGICS, INC.

2025-Q1 EPS reported $0.11 revenue$114,802,000

Q1 total revenue $114.8M (+40% YoY); GAAP net income $26.9M (+51% YoY); adjusted EBITDA $47.9M (+81% YoY).
FY2025 revenue guidance raised to >$500M; FY2026 to >$625M; adjusted EBITDA guidance >$235M and >$340M, respectively.
Board authorized $500M share repurchase program (~8% of market cap); timing and amount discretionary.
Debt reorganized: $30M borrowed on revolver to repay term loan; revolver outstanding $72.5M, term loan $2.5M; cost of debt down 1.1%.
FDA-approved yield enhancement process expected to increase IG output 20% from same plasma volume, supporting future growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.